Binxian Wei
Known title: DirectorCIK: 0001773586
Associated companies
Transaction History
| PALI | ▲ Buy | Grant | 592,300 | — | 6/10/2026 | View on chart |
| PALI | ▲ Buy | Option Exercise | 20,200 | — | 6/10/2026 | View on chart |
| PALI | ▲ Buy | Option Exercise | 388 | $0 | 11/21/2024 | View on chart |
| PALI | ▲ Buy | Option Exercise | 465 | $0 | 6/11/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108
Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108. Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.